SCHEMBL13035840

SCHEMBL13035840

COc1ccc(Cn2c(=O)c(C#N)c(-c3ccccc3)c3ccccc32)c(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 1/20 0.55
PDE1C Q14123 1/20 0.55
HTR3A P46098 1/20 0.52
EDNRB P24530 5/20 0.47
RXFP1 Q9HBX9 1/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.45
USP2 O75604 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 2/20 0.44
MAPK1 P28482 2/20 0.44
POLB P06746 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13035842 0.85 EDNRB (0.48) EDNRBMEN1KMT2AALDH1A1MAPT
SCHEMBL3481278 0.85 KCNA5 (0.54) PDE9APDE1CEDNRBMEN1KMT2A
SCHEMBL3622871 0.84 EDNRB (0.45) PDE9APDE1CEDNRBMEN1KMT2A
SCHEMBL4846578 0.77 ADORA2A (0.48) MEN1KMT2AALDH1A1USP2CYP1A2
SCHEMBL19577092 0.73 KDM4E (0.50) MEN1KMT2AALDH1A1USP2TSHR
SCHEMBL2641389 0.71 EDNRB (0.47) EDNRBALDH1A1MAPTMAPK1KCNA5
SCHEMBL11451983 0.70 HTR3A (0.86) PDE9APDE1CHTR3AALDH1A1USP2
SCHEMBL3622694 0.69 KCNA5 (0.51) KCNA5KCNH2KDM4E
SCHEMBL2863880 0.69 P2RX4 (0.62) PDE9APDE1CMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL3619565 0.69 EDNRB (0.46) EDNRBMEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825131-B2 Quinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-11-02 US disclosed
US-20070078154-A1 Quinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078154-A1 Quinoline potassium channel inhibitors KCNQ2, KCNQ1, KCNJ2 PDE9A 1895/4885PDE1C 889/4885HTR3A 2244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.